294 related articles for article (PubMed ID: 23009727)
1. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
Abelson JA; Murphy JD; Trakul N; Bazan JG; Maxim PG; Graves EE; Quon A; Le QT; Diehn M; Loo BW
Lung Cancer; 2012 Dec; 78(3):219-24. PubMed ID: 23009727
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
3. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
[TBL] [Abstract][Full Text] [Related]
5. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
6. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
[TBL] [Abstract][Full Text] [Related]
9. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
[TBL] [Abstract][Full Text] [Related]
10. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
[TBL] [Abstract][Full Text] [Related]
11. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
16. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
19. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
20. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
